CION Ameerpet
Understanding Your Report · Reviewed by CION Oncologists · NABH Accredited
Endometrial Cancer Grade — What Grade 1, 2 and 3 Mean
Grade and stage are two of the most confused words in this diagnosis, and they answer completely different questions. Grade describes how the cells look. Stage describes how far the cancer has gone. A Grade 3 tumour that has not left the lining is a very different situation from a Grade 1 tumour that has spread — and neither is the situation people usually imagine when they hear the number. This page explains what the grade on your report was measured from, what it changes about treatment, and why an increasing amount of the decision now rests on molecular testing rather than on the grade at all.
- Grade is about appearance — how closely the tumour cells still resemble normal lining tissue
- Stage is about extent — a separate question, answered mainly by the surgery — not by the biopsy
- Grade can change after surgery — a biopsy samples a fragment; the whole uterus tells the fuller story
- Molecular testing now sits alongside it — and in some cases it outweighs the grade entirely
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What the Grade Was Actually Measured From
Normal endometrium is made of glands — hollow, organised structures with a recognisable architecture. When endometrial cancer arises, it can keep making those glands, or it can lose the ability and grow instead as solid sheets of cells with no structure at all.
The FIGO grading system measures exactly that. The pathologist estimates how much of the tumour is growing as solid sheets rather than forming glands, and that proportion produces the number:
- Grade 1 — well differentiated. Almost all of the tumour still forms glands. It still looks broadly like the tissue it came from, and it tends to behave that way: slower growing, less likely to invade deeply into the muscle wall, less likely to reach lymph nodes.
- Grade 2 — moderately differentiated. A meaningful proportion has become solid, but glands remain. It sits between the other two in behaviour, and in practice is usually grouped with Grade 1 for treatment purposes.
- Grade 3 — poorly differentiated. More than half of the tumour grows as solid sheets. The cells have largely lost the character of the tissue they arose from, which is associated with deeper invasion and a higher chance of spread. See Grade 3 endometrial cancer.
- The nuclear adjustment. There is a second element: if the cell nuclei look markedly abnormal in a way that does not fit the architectural pattern, the grade is raised by one. This is why two tumours with a similar amount of solid growth can be graded differently.
One important limit: this scale applies to endometrioid carcinoma, the commonest form. Serous carcinoma, clear cell carcinoma and carcinosarcoma are regarded as high grade by definition and are not given a 1, 2 or 3 — see Type 2 endometrial cancer.
Did You Know? Grade is no longer the last word it once was. Endometrial cancers are now sorted into four molecular groups — POLE-mutated, mismatch repair deficient, p53-abnormal, and those with no specific molecular profile — and the group can matter more than the number. The clearest example is POLE: a tumour carrying a POLE mutation behaves remarkably well even when it looks aggressive down the microscope and is graded 3, and European guidance now supports de-escalating treatment for these women rather than treating them on the strength of grade alone. The reverse also holds — a p53-abnormal tumour is treated as high risk regardless of how modest the grade appears. This classification is built into the current FIGO staging system. Sources: FIGO 2023 staging system for cancer of the endometrium; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; World Health Organization classification of tumours of female reproductive organs.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Grade Is Not Stage — the Difference in One Table
This is the single commonest misunderstanding after a diagnosis, and it causes a great deal of unnecessary fear in both directions.
| Grade | Stage | |
|---|---|---|
| The question it answers | How abnormal do the cells look? How far has the tumour drifted from the tissue it came from? | How far has the cancer travelled? Is it confined to the uterus, or has it reached the cervix, the nodes, or beyond? |
| Where it comes from | The pathologist, examining tissue under a microscope. Available from the first biopsy, though it may be revised later. | Chiefly the operation, combined with imaging — how deep the invasion went, what the nodes showed. See FIGO staging. |
| What it is written as | Grade 1, 2 or 3 — or increasingly “low grade” (1–2) and “high grade” (3). | Stage I to IV, with letter subdivisions. Stage 1 means confined to the body of the uterus. |
| Can it change? | Yes. A biopsy samples a fragment; examining the whole uterus after surgery quite often shifts the grade, in either direction. | Yes, and this is expected. Pre-operative stage is provisional; the definitive stage comes from the surgical specimen. |
| What it decides | How aggressively the tumour is likely to behave, and therefore how much treatment is considered after surgery. | How much surgery is needed, and whether treatment beyond the pelvis is required. |
| Which matters more? | Neither on its own. They are combined, along with depth of muscle invasion, lymphovascular invasion and molecular group, into a single risk assessment. | Same answer. A high-grade early-stage tumour and a low-grade later-stage tumour can end up with quite similar plans. |
If you take one line from this page: a grade on its own does not tell you your outlook, and neither does a stage on its own. What determines the plan is the combination — grade, stage, depth of invasion into the muscle wall, whether lymphovascular spaces are involved, and which molecular group the tumour falls into. Ask for all five, not just the two numbers.
Confused About What Your Grade Means?
Bring the pathology report. Forty-five minutes is long enough to go through grade, stage, invasion and markers together, and explain what follows from the combination.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Number on a Report Is Not a Prognosis
What the grade means for you depends on four other things written on the same page. Ask someone to read all of them together.
What the Grade Actually Changes
Grade rarely changes whether surgery happens — almost all endometrial cancer is treated surgically first. What it changes is what surrounds the surgery.
Before surgery
How Much Imaging Is Done
A high-grade tumour prompts more thorough pre-operative imaging, because the chance of spread beyond the uterus is higher and the operation is planned around what is found.
During surgery
Whether Nodes Are Assessed
Grade feeds into whether lymph nodes are sampled and how. See sentinel node biopsy, which gives staging information at lower risk of leg lymphoedema.
After surgery
The Adjuvant Decision
This is where grade earns its keep. It is one of the main inputs into whether anything follows the operation at all. See the adjuvant decision.
After surgery
Which Treatment, If Any
Low grade and early stage often needs nothing, or a short course of vault brachytherapy. Higher grade may bring in pelvic radiation or drug treatment.
Fertility
Whether the Uterus Can Be Kept
Fertility-sparing treatment is generally confined to Grade 1 tumours with no muscle invasion. Grade is one of the first eligibility questions. See who is eligible.
Afterwards
How Closely You Are Followed
Higher grade means a higher chance of recurrence and generally closer surveillance in the first years. See the follow-up schedule.
Reading the pathology
The Five Things on Your Report That Decide the Plan
Grade is only one of them, and on its own it is the least informative. If you are going to ask your oncologist about anything, ask about all five together.
Grade — how the cells look
The 1, 2 or 3 discussed above, based on how much of the tumour grows as solid sheets rather than glands, adjusted for nuclear appearance. Increasingly it is collapsed into two categories, low grade covering 1 and 2 and high grade covering 3, because that division tracks behaviour more usefully than the three-point scale and because the distinction between Grade 1 and Grade 2 is one of the less reproducible calls in pathology. If your report says low grade or high grade rather than a number, nothing has been left out.
Depth of invasion into the muscle wall
The uterus has a thick muscular wall, the myometrium, beneath the lining. How far the tumour has grown into it is one of the strongest predictors of whether cancer has reached the lymph nodes, and it is a separate measurement from grade. Invasion of less than half the wall thickness and invasion of more than half are treated as meaningfully different, and the distinction sits directly in the FIGO staging system. This is one of the main things the surgery establishes that a biopsy simply cannot.
Lymphovascular space invasion
Reported as LVSI, this describes whether tumour cells are seen inside the small lymphatic and blood vessels within the uterine wall. It indicates that the tumour has found a route by which it can travel, and it is an independent risk factor: substantial LVSI raises the risk category even where grade and depth of invasion are modest, and it is one of the commonest reasons a woman with an apparently early tumour is offered treatment after surgery. Reports may distinguish focal from substantial involvement, and that distinction matters.
Histological type
Grade only means what this page describes if the tumour is endometrioid. Serous carcinoma, clear cell carcinoma and carcinosarcoma are different diseases in behaviour, are regarded as high grade by definition, and are managed more aggressively even when found early. Reading a report and looking for a grade number, without first checking the type, is a common route to misunderstanding it. See uterine cancer types.
Molecular group
Four groups: POLE-mutated, mismatch repair deficient, p53-abnormal, and no specific molecular profile. They carry genuinely different outlooks and are now built into FIGO staging. POLE-mutated tumours do unusually well even when high grade, and may warrant less treatment rather than more. p53-abnormal tumours are treated as high risk regardless of grade. Mismatch repair deficiency additionally flags who should be offered Lynch syndrome counselling and who may respond to immunotherapy. See MMR and MSI testing.
And one thing that is not on the report: you
Age, general health, other medical conditions and what you want from treatment all shape what is reasonable, and none of them appear in the pathology. Two women with identical reports can properly end up with different plans — one accepting a short course of vault brachytherapy, another declining it after weighing a small absolute benefit against the inconvenience. That is a legitimate conversation to have, and a good tumour board discussion includes it rather than reading the plan off a table.
Want Your Grade, Stage and Markers Explained Together?
They only mean something in combination. Bring the report and we will go through all of it, including what it implies for treatment after surgery. The opinion is free.
Why Your Grade Might Change After Surgery
It is unsettling to be told one grade before the operation and a different one afterwards, and it happens often enough to be worth explaining in advance. It is not usually an error.
An endometrial biopsy takes a small sample of a lining that may not be uniform. If the tumour has a low-grade area and a high-grade area, the sample may catch only one of them. When the whole uterus is examined, the pathologist sees all of it — and the grade reported is the one that reflects the full tumour.
- It moves in both directions. Grades are revised up and revised down. A tumour that looked Grade 3 on a small fragment can prove to be predominantly Grade 1 across the whole specimen.
- The type can be revised too. Occasionally what was called endometrioid turns out to have a serous or clear cell component that the biopsy did not reach, which is a more significant change than a shift in grade.
- The definitive answer is the surgical specimen. Treatment decisions after the operation are made on the final pathology, not on the pre-operative biopsy — which is exactly why the adjuvant conversation happens after surgery rather than before it.
- It is a reason to be cautious about planning too far ahead. If you have been given a provisional grade and a provisional plan, both are provisional. That is not evasion; it is honest sequencing.
Types, Grades and Staging — Every Guide
This page is the starting point for the pathology side of the diagnosis. Each guide below goes one level deeper.
- Type 1 (endometrioid) endometrial cancer
- Type 2 (non-endometrioid) endometrial cancer
- Uterine serous carcinoma
- Uterine clear cell carcinoma
- Uterine carcinosarcoma (MMMT)
- Endometrioid adenocarcinoma explained
- Uterine sarcoma — how it differs from endometrial cancer
- Uterine leiomyosarcoma
- Uterine cancer types — an overview
- FIGO staging for endometrial cancer explained
- Stage 1 endometrial cancer — what it means & outlook
- Stage 2 endometrial cancer — what it means & treatment
- Stage 3 endometrial cancer — what it means & treatment
- Stage 4 (metastatic) endometrial cancer — what it means
- Grade 3 endometrial cancer — why it's treated differently
- Lymph node involvement in endometrial cancer
- How recurrent endometrial cancer is found
- Endometrial vs cervical cancer — how they differ
- Endometrial vs ovarian cancer — how they differ
Why Pathology Is Worth a Second Read
Grade decides how much treatment is proposed. Where that call is finely balanced, it is worth having it made carefully.
Slides reviewed, not just the summary line
MMR / MSI testing as standard
Tumour board for every diagnosis
Named MCh surgical oncologists
Sentinel node mapping where it fits
Decisions for healing, not billing
Take The Next Step
You Are Entitled to Understand Your Own Pathology Report
It is written for other doctors, which is why it reads the way it does. One appointment is usually enough to translate it.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Endometrial Cancer Grade — Frequently Asked Questions
What is the difference between grade and stage in endometrial cancer?
They answer different questions and are decided by different things. Grade describes how the tumour cells look under a microscope — specifically, how much of the tumour grows as solid sheets rather than forming the glands normal endometrium is made of. It is assigned by a pathologist and is available from the first biopsy. Stage describes how far the cancer has travelled: whether it is confined to the body of the uterus, has reached the cervix, the lymph nodes, or organs beyond. Stage comes mainly from the surgery, combined with imaging. Neither number means much alone. A Grade 3 tumour confined to the lining and a Grade 1 tumour that has reached the nodes are very different situations, and it is the combination that determines treatment.
Is Grade 1 endometrial cancer serious?
It is cancer, so it is taken seriously and it is treated — but Grade 1 is the most favourable of the three, and the great majority of endometrial cancers found in India and worldwide are low grade and early stage. Grade 1 means almost all of the tumour still forms glands and still resembles the tissue it arose from, which correlates with slower growth, less deep invasion into the muscle wall, and a lower chance of lymph node involvement. Many Grade 1, early-stage tumours are treated with surgery alone and need nothing afterwards. That said, grade is only one of five factors; depth of invasion, lymphovascular invasion, histological type and molecular group all feed into the final assessment.
Can the grade of my cancer change after surgery?
Yes, and it happens often enough that it is worth expecting. An endometrial biopsy takes a small sample of a lining that may not be uniform, so if the tumour contains both lower-grade and higher-grade areas, the biopsy may have caught only one of them. Once the whole uterus is examined after surgery, the pathologist sees the full tumour and reports the grade that reflects all of it. Revisions go in both directions — grades are lowered as often as they are raised — and occasionally the histological type is revised too. This is why decisions about treatment after surgery are made on the final surgical pathology rather than on the pre-operative biopsy.
What does "high-grade endometrial cancer" mean?
High grade usually means Grade 3 endometrioid carcinoma — more than half the tumour growing as solid sheets rather than glands. Increasingly, reports use "low grade" for Grades 1 and 2 together and "high grade" for Grade 3, because that two-way split tracks tumour behaviour more reliably than the three-point scale, and because distinguishing Grade 1 from Grade 2 is one of the less reproducible judgements in pathology. High grade is also used for the non-endometrioid types — serous, clear cell and carcinosarcoma — which are regarded as high grade by definition and are not graded 1 to 3 at all. High grade means more thorough staging and a greater likelihood of treatment after surgery; it does not by itself mean advanced disease.
Does molecular testing matter more than grade now?
In some cases, yes — which is a genuine change in how this disease is understood. Endometrial cancers are now sorted into four molecular groups: POLE-mutated, mismatch repair deficient, p53-abnormal, and no specific molecular profile. These groups are built into the current FIGO staging system and into European treatment guidance. The clearest example of the shift is POLE: a POLE-mutated tumour behaves very favourably even when it is graded 3 and looks aggressive, and guidance now supports giving such women less treatment rather than more. Conversely, a p53-abnormal tumour is managed as high risk whatever its grade. Grade has not become irrelevant, but it is no longer read on its own.
Medical disclaimer: This page explains how endometrial cancer is graded and is reviewed by a CION oncologist, following the FIGO staging system, the World Health Organization classification, and current NCCN and ESGO–ESTRO–ESP guidance. It is general information about how pathology reports are constructed, not an interpretation of your individual report, and it does not predict an outcome for any particular woman. Treatment decisions should be made with the oncology team that holds your full pathology.